ArticleScientific reports2025
Incidence and site specific characteristics of angiosarcoma in Japan using a population-based national cancer registry from 2016 to 2019.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Angiosarcoma is so rare, no reports on its epidemiology and prognosis using nationwide population-based data exist. The present study aimed to clarify the characteristics and clinical outcomes of angiosarcoma using the National Cancer Registry (NCR) in Japan. We analyzed data from 23,522 patients with soft-tissue sarcomas (STS), entered in the NCR in 2016-2019 using the International Classification of Diseases-Oncology, Third Edition cancer topography and morphology codes. We extracted demographics, tumor details, treatment, and prognosis for each patient. Of 23,522 STS patients, 1,973 patients were enrolled in the angiosarcoma group and 21,549 in the non-angiosarcoma group. Angiosarcoma accounts for 8.4% of all STS (adjusted incidence: 0.18/100,000/year). Most angiosarcoma patients were men (58.7%) and the most common tumor location was the head/neck (51.0%). In the angiosarcoma group (compared to the non-angiosarcoma group): age at diagnosis was significantly older; more tumors were localized; chemotherapy and radiotherapy were more common; surgery was less common; and the overall survival was significantly worse (P < 0.001). Several factors were associated with worse overall survival in the multivariate analyses. The present study is the first to have clarified the epidemiology, clinical features, treatment, prognosis, and significant factors affecting prognosis of patients with angiosarcoma in Japan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.